EMBO Molecular Medicine (Dec 2015)

Molecular cause and functional impact of altered synaptic lipid signaling due to a prg‐1 gene SNP

  • Johannes Vogt,
  • Jenq‐Wei Yang,
  • Arian Mobascher,
  • Jin Cheng,
  • Yunbo Li,
  • Xingfeng Liu,
  • Jan Baumgart,
  • Carine Thalman,
  • Sergei Kirischuk,
  • Petr Unichenko,
  • Guilherme Horta,
  • Konstantin Radyushkin,
  • Albrecht Stroh,
  • Sebastian Richers,
  • Nassim Sahragard,
  • Ute Distler,
  • Stefan Tenzer,
  • Lianyong Qiao,
  • Klaus Lieb,
  • Oliver Tüscher,
  • Harald Binder,
  • Nerea Ferreiros,
  • Irmgard Tegeder,
  • Andrew J Morris,
  • Sergiu Gropa,
  • Peter Nürnberg,
  • Mohammad R Toliat,
  • Georg Winterer,
  • Heiko J Luhmann,
  • Jisen Huai,
  • Robert Nitsch

DOI
https://doi.org/10.15252/emmm.201505677
Journal volume & issue
Vol. 8, no. 1
pp. 25 – 38

Abstract

Read online

Abstract Loss of plasticity‐related gene 1 (PRG‐1), which regulates synaptic phospholipid signaling, leads to hyperexcitability via increased glutamate release altering excitation/inhibition (E/I) balance in cortical networks. A recently reported SNP in prg‐1 (R345T/mutPRG‐1) affects ~5 million European and US citizens in a monoallelic variant. Our studies show that this mutation leads to a loss‐of‐PRG‐1 function at the synapse due to its inability to control lysophosphatidic acid (LPA) levels via a cellular uptake mechanism which appears to depend on proper glycosylation altered by this SNP. PRG‐1+/− mice, which are animal correlates of human PRG‐1+/mut carriers, showed an altered cortical network function and stress‐related behavioral changes indicating altered resilience against psychiatric disorders. These could be reversed by modulation of phospholipid signaling via pharmacological inhibition of the LPA‐synthesizing molecule autotaxin. In line, EEG recordings in a human population‐based cohort revealed an E/I balance shift in monoallelic mutPRG‐1 carriers and an impaired sensory gating, which is regarded as an endophenotype of stress‐related mental disorders. Intervention into bioactive lipid signaling is thus a promising strategy to interfere with glutamate‐dependent symptoms in psychiatric diseases.

Keywords